In conclusion, the evidence that in CLL cells, Jag1 is processed and associated with their survival, and Notch1/2 activation occurs independently of Jag1 expressed on these cells, suggests the rationale for new therapeutic approaches targeting the Notch-ligand system in CLL (Fig. 10). The gene discussed is NOTCH1; the disease is B-cell chronic lymphocytic leukemia.